Juno Therapeutics (JUNO) shares have surged in pre-market trading today after the FDA removed its clinical hold on the company’s Phase 2 clinical trial, ROCKET, evaluating its lead CAR-T candidate JCAR015 for the treatment of adult patients with relapsed/refractory B cell acute lymphoblastic leukemia. The clinical hold was placed recently after two patients died after receiving the preconditioning regimen of cyclophosphamide + fludarabine. Going forward, the study participants will be preconditioned with cyclophosphamide only.